share_log

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A:并购重组委托声明
美股SEC公告 ·  2024/09/24 05:13

Moomoo AI 已提取核心信息

Cardio Diagnostics Holdings, Inc. (Cardio Diagnostics) has announced its plans to conduct a reverse stock split, subject to shareholder approval. The reverse stock split aims to increase the per-share trading price of the company's common stock to comply with the Nasdaq Capital Market's minimum bid price requirement. The proposed amendment to Cardio Diagnostics' Certificate of Incorporation would allow for a reverse stock split at a ratio between 1-for-5 and 1-for-40, with the exact ratio to be determined by the Board of Directors. The reverse stock split is intended to maintain the company's listing on the Nasdaq and make its stock more attractive to a broader range of investors. The Board of Directors has recommended the reverse stock split as being in the best interests of the company and its shareholders. The announcement also includes details about the upcoming annual meeting of stockholders, scheduled for November 15, 2024, where the reverse stock split will be put to a vote.
Cardio Diagnostics Holdings, Inc. (Cardio Diagnostics) has announced its plans to conduct a reverse stock split, subject to shareholder approval. The reverse stock split aims to increase the per-share trading price of the company's common stock to comply with the Nasdaq Capital Market's minimum bid price requirement. The proposed amendment to Cardio Diagnostics' Certificate of Incorporation would allow for a reverse stock split at a ratio between 1-for-5 and 1-for-40, with the exact ratio to be determined by the Board of Directors. The reverse stock split is intended to maintain the company's listing on the Nasdaq and make its stock more attractive to a broader range of investors. The Board of Directors has recommended the reverse stock split as being in the best interests of the company and its shareholders. The announcement also includes details about the upcoming annual meeting of stockholders, scheduled for November 15, 2024, where the reverse stock split will be put to a vote.
Cardio Diagnostics Holdings, Inc.(以下简称Cardio Diagnostics)宣布计划进行股票的反向股权分置,需得股东批准。该反向股权分置旨在提高公司普通股的每股交易价格,以符合纳斯达克资本市场的最低买入价要求。Cardio Diagnostics的公司章程拟议中的修正案将允许以1比5至1比40的比例进行反向股权分置,具体比例将由董事会决定。反向股权分置旨在维持公司在纳斯达克的上市地位,并使其股票更具吸引力吸引更广泛的投资者。董事会已建议进行反向股权分置,认为这符合公司及其股东的最佳利益。该公告还包括有关即将举行的股东年度会议的详细信息,计划于2024年11月15日举行,届时将就反向股权分置进行表决。
Cardio Diagnostics Holdings, Inc.(以下简称Cardio Diagnostics)宣布计划进行股票的反向股权分置,需得股东批准。该反向股权分置旨在提高公司普通股的每股交易价格,以符合纳斯达克资本市场的最低买入价要求。Cardio Diagnostics的公司章程拟议中的修正案将允许以1比5至1比40的比例进行反向股权分置,具体比例将由董事会决定。反向股权分置旨在维持公司在纳斯达克的上市地位,并使其股票更具吸引力吸引更广泛的投资者。董事会已建议进行反向股权分置,认为这符合公司及其股东的最佳利益。该公告还包括有关即将举行的股东年度会议的详细信息,计划于2024年11月15日举行,届时将就反向股权分置进行表决。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息